Lilly touts Emgality's ability to reduce migraine patients' overall pain in first look at 'holistic approach'

Lilly touts Emgality's ability to reduce migraine patients' overall pain in first look at 'holistic approach'

Submitted by admin on June 17, 2020 - 9:52pm
Source: 
Fierce Pharma
News Tags: 
Eli Lilly
migraines
Amgen
Teva Pharmaceutical
Lundbeck
Emgality
Headline: 
Lilly touts Emgality's ability to reduce migraine patients' overall pain in first look at 'holistic approach'
snippet: 

Eli Lilly is facing off against Amgen, Teva and Lundbeck in the competitive field of CGRP migraine prevention drugs, and the drugmaker is now touting data showing that its Emgality can reduce total pain burden for patients, a class first. 

In three randomized studies, episodic migraine patients on Emgality experienced 68.6 fewer hours of severity-weighted pain per month on average, compared with 36.2 for placebo, Lilly said Tuesday

Do Not Allow Advertisers to Use My Personal information